Liraglutide, a glucagon-like peptide receptor agonist (GLP1-RA), shares high amino acid sequence homology with GLP-1, was first approved for type 2 diabetes and later approved for treatment of common obesity; it reduces appetite and leads to weight loss in obesity caused by MC4R pathogenic variants. Here, MC4R is linked to Obesity.